预约演示
更新于：2026-02-27
Penehyclidine hydrochloride
盐酸戊乙奎醚
更新于：2026-02-27
概要
基本信息
原研机构 |
非在研机构- |
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C20H30ClNO2 |
InChIKeyDDTVVMRZNVIVQM-UHFFFAOYSA-N |
CAS号151937-76-7 |
关联
48
项与 盐酸戊乙奎醚 相关的临床试验ChiCTR2500107865
Effect of Penehyclidine Combined with Flurbiprofen Axetil on Catheter-Related Bladder Discomfort after General Anesthesia
ChiCTR2500107170
The Effect of Penehyclidine Hydrochloride on Preventing Postoperative Nausea and Vomiting in Patients Undergoing Thyroid Surgery Under General Anesthesia: A Randomized Double-Blind Controlled Study
ChiCTR2500105868
Effect of Low-Dose Esketamine Combined with Propofol Anesthesia Versus Conventional Anesthesia on Hypotension Incidence in Ambulatory Hysteroscopy: A Randomized Controlled Trial
100 项与 盐酸戊乙奎醚 相关的临床结果
登录后查看更多信息
100 项与 盐酸戊乙奎醚 相关的转化医学
登录后查看更多信息
100 项与 盐酸戊乙奎醚 相关的专利（医药）
登录后查看更多信息
224
项与 盐酸戊乙奎醚 相关的文献（医药）2025-10-01JOURNAL OF INTERNATIONAL MEDICAL RESEARCH
Comparison of the effect of preoperative glycopyrrolate and penehyclidine hydrochloride on postoperative nausea and vomiting in patients undergoing laparoscopic cholecystectomy: A randomized controlled trial
Article
作者: Ao, Renrong ; Yan, Hui ; Xia, Rui ; Fan, Chenghui
Objective:
To investigate the effect of preoperative glycopyrrolate and penehyclidine hydrochloride on postoperative nausea and vomiting in patients undergoing laparoscopic cholecystectomy.
Methods:
This prospective, randomized, double-blind, controlled trial enrolled 120 patients who underwent laparoscopic cholecystectomy. Patients were randomly assigned to the glycopyrrolate group, penehyclidine hydrochloride group, or normal saline group. Postoperative nausea and vomiting, hemodynamic parameters, anesthetic consumption, duration of postanesthesia care unit stay, and other perioperative adverse events were recorded.
Results:
The incidence of postoperative nausea and vomiting within 1 h in the penehyclidine hydrochloride group was significantly lower than that in the normal saline and glycopyrrolate groups. The heart rate at immediately prior to anesthesia induction, 1 min after endotracheal intubation, the start of surgery, 2 min after pneumoperitoneum, and cholecyst dissection and mean arterial pressure at 1 min after endotracheal intubation and the start of surgery in the normal saline group were significantly lower than those in the glycopyrrolate group. The heart rate at immediately prior to anesthesia induction, 1 min after endotracheal intubation, the start of surgery, and 2 min after pneumoperitoneum and mean arterial pressure at 1 min after endotracheal intubation in the penehyclidine hydrochloride group were markedly lower than those in the glycopyrrolate group. The incidence of bradycardia in the normal saline and penehyclidine hydrochloride groups was significantly higher than that in the glycopyrrolate group.
Conclusions:
Penehyclidine hydrochloride is more effective than glycopyrrolate in preventing postoperative nausea and vomiting in patients undergoing laparoscopic cholecystectomy, particularly in the early postoperative period.Chinese Clinical Trial Registry number:
ChiCTR2500107519
2025-09-01JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
Study on the mechanism of action of Penehyclidine hydrochloride on LPS-induced acute lung injury by regulating autophagy through the mTOR/Keap1/Nrf2 signaling pathway
Article
作者: Weng, Shuoyun ; Chen, Zhicheng ; Liu, Danjuan ; Huang, Shanjiao ; Weng, Junting ; Guo, Rongjie ; Shi, Bingbing
Acute lung injury (ALI) is a clinical syndrome characterized by pulmonary inflammation and edema, leading to impaired oxygenation and respiratory failure. Penehyclidine hydrochloride (PHC) has anticholinergic, anti-inflammatory, and antioxidant properties. In this paper, we investigated the protective role of PHC in ALI and explored its mechanism of action. Both in vivo and in vitro experiments were performed using LPS induction to establish an ALI model. Following PHC intervention, the assessment of lung injury was conducted using pathological section examination, mouse lung injury scoring, and ELISA to measure oxidative stress markers including myeloperoxidase (MPO), malondialdehyde (MDA), Super Oxide Dismutase (SOD), and Glutathione Peroxidase (GSH-Px), as well as inflammatory cytokine levels of TNF-α, IL-1β, and IL-18. Immunoblotting and immunofluorescence assays were employed to detect autophagy markers and the mTOR/Keap1/Nrf2 signaling pathway. To confirm the role of autophagy in the protective effects of PHC against ALI, we administered PHC in combination with Rapamycin (RAPA) or 3-Methyladenine (3-MA) to the model groups and evaluated the aforementioned parameters. Our findings revealed that in the LPS-induced ALI model, there was significant pulmonary histopathological damage and increased levels of MPO, MDA, TNF-α, IL-1β, and IL-18, along with decreased levels of SOD and GSH-Px in lung tissue or serum. These alterations were all reversed following PHC treatment. Additionally, compared to the ALI group, PHC administration reversed the expression of mTOR/Keap1/Nrf2 and autophagy proteins LC3, Beclin-1 and p62 induced by LPS. Treatment with the mTOR inhibitor (autophagy inducer RAPA) blocked the protective effects of PHC on lung injury, the mTOR/Keap1/Nrf2 signaling pathway, and autophagy, while co-treatment with the autophagy inhibitor 3-MA showed a significant protective effect on ALI. The results suggest that PHC has a notable protective effect on ALI, which may be achieved by modulating the mTOR/Keap1/Nrf2 signaling pathway to inhibit autophagy.
2025-08-01Journal of PeriAnesthesia Nursing
Penehyclidine Hydrochloride: A Promising Antimuscarinic Agent for PONV Prophylaxis in Diverse Surgical Procedures
Review
作者: Saber, Taisir ; AlHussaini, Khalid I ; Alkheder, Ahmad ; Abo Zeid, Mohamed ; Elrosasy, Amr ; Aissa, Sara Chikh ; Hawas, Yousef ; El-Nablaway, Mohammad ; Sarhan, Khalid ; Khodeer, Dina M ; Abu Salah, Mariam A
PURPOSE:
The purpose of this meta-analysis is to measure the effectiveness of penehyclidine hydrochloride hydrate (PHC)-an antimuscarinic drug-in preventing postoperative nausea and vomiting (PONV) for different surgeries.
DESIGN:
Meta-analysis.
METHODS:
According to the Preferred Reporting Items for Systematic reviews and Meta-Analyses guidelines, we conducted an online literature search using PubMed, Web of Science, Scopus, and Embase databases. Randomized control trials comparing PHC with placebo or any other standard treatments were included.
FINDINGS:
Our systematic review screened 54 articles, and four randomized control trials with 766 patients were included. There was no significant difference between PHC and the control group for the prevention of postoperative vomiting (risk ratio [RR] = 0.43). However, the subgroup analysis showed some promise. At 24 hours, PHC significantly decreased the incidence of postoperative nausea (RR = 0.31), postoperative vomiting (RR = 0.17), and PONV (RR = 0.33). While at 48 hours, PHC showed nonsignificant results for the same outcomes. PHC did not result in significantly higher rates of analgesia use, headache, dizziness, longer durations of stay in the postanesthesia care unit, or longer duration for extubation, but it showed significantly lower results for the use of antiemetics. Furthermore, PHC showed higher rates of dry mouth.
CONCLUSIONS:
The findings suggest that PHC offers a promising option for PONV prophylaxis, particularly in surgical settings where early PONV are prevalent, with an acceptable safety profile. Further research is recommended to optimize dosing strategies and compare PHC with established antiemetics.
100 项与 盐酸戊乙奎醚 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 麻醉 | 中国 | 2002-10-24 | |
| 药物中毒 | 中国 | 2002-10-24 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 胆道痛 | 临床2期 | 中国 | 2017-05-19 | |
| 胆道痉挛 | 临床2期 | 中国 | 2017-05-19 | |
| 慢性阻塞性肺疾病 | 临床2期 | 中国 | 2008-07-21 | |
| 脓毒性休克 | 临床1期 | 中国 | 2012-06-11 | |
| 帕金森病 | 临床1期 | 中国 | 2012-03-15 | |
| 休克 | 临床1期 | 中国 | 2012-03-15 | |
| 平滑肌痉挛 | 临床1期 | 中国 | 2012-03-15 | |
| 急性肺损伤 | 临床前 | 中国 | 2025-09-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | - | 100 | 鹽膚鹹鏇鹹繭觸壓願簾(蓋範夢網壓構窪網襯觸) = 鹹簾鑰膚繭鏇積觸齋繭 衊繭糧選膚醖築鏇淵範 (鬱構簾鬱製積鬱糧網鏇 ) | - | 2022-10-14 | ||
TIVA group | 鹽膚鹹鏇鹹繭觸壓願簾(蓋範夢網壓構窪網襯觸) = 願願鑰顧壓壓鬱鏇築襯 衊繭糧選膚醖築鏇淵範 (鬱構簾鬱製積鬱糧網鏇 ) | ||||||
临床3期 | - | 864 | 糧選襯齋餘淵廠遞築繭(遞膚願餘範獵夢餘餘夢) = dry mouth and delirium 齋繭醖餘鏇鏇艱製膚壓 (衊糧積齋構簾遞構齋鑰 ) | 积极 | 2022-04-01 | ||
Placebo | |||||||
临床4期 | 228 | 淵廠鹹鬱夢願憲膚膚窪(襯觸憲鹽鏇鹽餘艱齋衊) = 餘淵齋窪願範鹽餘願壓 繭膚鏇襯獵鏇製觸窪壓 (鹽簾餘齋膚廠蓋鬱艱衊 ) 更多 | - | 2021-02-13 | |||
淵廠鹹鬱夢願憲膚膚窪(襯觸憲鹽鏇鹽餘艱齋衊) = 蓋齋衊膚製淵積鹽廠窪 繭膚鏇襯獵鏇製觸窪壓 (鹽簾餘齋膚廠蓋鬱艱衊 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用